KRAS and ovarian carcinoma: The prevalence of the KRAS-variant was 38.5% (n = 20/52) in patients recruited within two years of their ovarian cancer diagnosis, which was significantly higher than the prevalence in patients recruited more than 2 years after their ovarian cancer diagnosis (16.7%, n = 5/30, p<0.048 by Exact test) (Table 2).